![Malken Bayrakdarian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Malken Bayrakdarian
Direttore/Membro del Consiglio presso NuChem Sciences, Inc.
Posizioni attive di Malken Bayrakdarian
Società | Posizione | Inizio | Fine |
---|---|---|---|
NuChem Sciences, Inc.
![]() NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Malken Bayrakdarian
Statistiche
Distribuzione geografica
Canada | 2 |
Posizioni
Director/Board Member | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
NuChem Sciences, Inc.
![]() NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Health Technology |
- Borsa valori
- Insiders
- Malken Bayrakdarian
- Esperienza